{"id":3978,"date":"2009-04-21T09:57:00","date_gmt":"2009-04-21T09:57:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=3978"},"modified":"2022-11-10T14:24:14","modified_gmt":"2022-11-10T14:24:14","slug":"an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/","title":{"rendered":"An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn\u2019s disease."},"content":{"rendered":"
\n

Atsushi Sakuraba<\/a> 1<\/a><\/sup>, Satoshi Motoya<\/a>, Kenji Watanabe<\/a>, Masakazu Nishishita<\/a>, Kazunari Kanke<\/a>, Toshiyuki Matsui<\/a>, Yasuo Suzuki<\/a>, Tadayuki Oshima<\/a>, Reiko Kunisaki<\/a>, Takayuki Matsumoto<\/a>, Hiroyuki Hanai<\/a>, Ken Fukunaga<\/a>, Naoki Yoshimura<\/a>, Toshimi Chiba<\/a>, Shinsuke Funakoshi<\/a>, Nobuo Aoyama<\/a>, Akira Andoh<\/a>, Hiroshi Nakase<\/a>, Yohei Mizuta<\/a>, Ryoichi Suzuki<\/a>, Taiji Akamatsu<\/a>, Masahiro Iizuka<\/a>, Toshifumi Ashida<\/a>, Toshifumi Hibi<\/a>, Am J Gastroenterol. 2009 Dec;104(12):2990-5.<\/p>\n<\/div>\n\n

\n

Background: Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn\u2019s disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This study was performed to assess clinical efficacy and safety of intensive GMA in patients with active CD.<\/strong> Methods: In an open-label, prospective, randomized multicentre setting, 104 patients with CD activity index (CDAI) of 200 to 450 received intensive GMA, at two sessions per week (n<\/em>\u00a0= 55) or one session per week (n<\/em>\u00a0= 49). Clinical remission was defined as a CDAI score <150. Patients in each arm could receive up to 10 GMA sessions. However, GMA treatment could be discontinued when CDAI decreased to <150 (clinical remission level).<\/strong> Results: Of the 104 patients, 99 were available for efficacy evaluation as per protocol, 45 in the weekly GMA group, and 54 in the intensive GMA group. Remission was achieved in 16 of 45 patients (35.6 %) in the weekly GMA and in 19 of 54 (35.2 %) in the intensive GMA (NS). Further, the mean time to remission was 35.4 \u00b1 5.3 days in the weekly GMA and 21.7 \u00b1 2.7 days in the intensive GMA (P<\/em>\u00a0= 0.0373). Elevated leucocytes and erythrocyte sedimentation rate were significantly improved by intensive GMA, from 8005\/\u03bcL to 6950\/\u03bcL (P<\/em>\u00a0= 0.0461) and from 54.5 mm\/hr to 30.0 mm\/hr (P<\/em>\u00a0= 0.0059), respectively. In both arms, GMA was well tolerated and was without safety concern.<\/strong> Conclusions: In this study, with respect to remission rate, intensive GMA was not superior to weekly GMA, but the time to remission was significantly shorter in the former without increasing the incidence of side effects. UMIN registration # 000003666<\/strong>.<\/h4>\n<\/div>\n\n
\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/26585569\/<\/a><\/p>\n<\/div>\n\n

\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4653849\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Atsushi Sakuraba 1, Satoshi Motoya, Kenji Watanabe, Masakazu Nishishita, Kazunari Kanke, Toshiyuki Matsui, Yasuo Suzuki, Tadayuki Oshima, Reiko Kunisaki, Takayuki Matsumoto, Hiroyuki Hanai, Ken Fukunaga, Naoki Yoshimura, Toshimi Chiba, Shinsuke Funakoshi, Nobuo Aoyama, Akira Andoh, Hiroshi Nakase, Yohei Mizuta, Ryoichi Suzuki, Taiji Akamatsu, Masahiro Iizuka, Toshifumi Ashida, Toshifumi Hibi, Am J Gastroenterol. 2009 Dec;104(12):2990-5. Background: Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn\u2019s disease (CD). However, with routine weekly therapy, it may take […]<\/p>\n","protected":false},"template":"","scientific_tags":[330,303,159,317,153,100,96,97,85],"class_list":["post-3978","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-trial","scientific_tags-combination","scientific_tags-crohns-disease","scientific_tags-delayed-response","scientific_tags-morbidity","scientific_tags-multicenter","scientific_tags-open-label","scientific_tags-prospective","scientific_tags-randomized"],"acf":{"sc_authors":""},"yoast_head":"\nAn open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn\u2019s disease. - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn\u2019s disease. - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Atsushi Sakuraba 1, Satoshi Motoya, Kenji Watanabe, Masakazu Nishishita, Kazunari Kanke, Toshiyuki Matsui, Yasuo Suzuki, Tadayuki Oshima, Reiko Kunisaki, Takayuki Matsumoto, Hiroyuki Hanai, Ken Fukunaga, Naoki Yoshimura, Toshimi Chiba, Shinsuke Funakoshi, Nobuo Aoyama, Akira Andoh, Hiroshi Nakase, Yohei Mizuta, Ryoichi Suzuki, Taiji Akamatsu, Masahiro Iizuka, Toshifumi Ashida, Toshifumi Hibi, Am J Gastroenterol. 2009 Dec;104(12):2990-5. Background: Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn\u2019s disease (CD). However, with routine weekly therapy, it may take […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-10T14:24:14+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/\",\"name\":\"An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn\u2019s disease. - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2009-04-21T09:57:00+00:00\",\"dateModified\":\"2022-11-10T14:24:14+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn\u2019s disease. - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/","og_locale":"es_ES","og_type":"article","og_title":"An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn\u2019s disease. - Adacyte","og_description":"Atsushi Sakuraba 1, Satoshi Motoya, Kenji Watanabe, Masakazu Nishishita, Kazunari Kanke, Toshiyuki Matsui, Yasuo Suzuki, Tadayuki Oshima, Reiko Kunisaki, Takayuki Matsumoto, Hiroyuki Hanai, Ken Fukunaga, Naoki Yoshimura, Toshimi Chiba, Shinsuke Funakoshi, Nobuo Aoyama, Akira Andoh, Hiroshi Nakase, Yohei Mizuta, Ryoichi Suzuki, Taiji Akamatsu, Masahiro Iizuka, Toshifumi Ashida, Toshifumi Hibi, Am J Gastroenterol. 2009 Dec;104(12):2990-5. Background: Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn\u2019s disease (CD). However, with routine weekly therapy, it may take […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/","og_site_name":"Adacyte","article_modified_time":"2022-11-10T14:24:14+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/","name":"An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn\u2019s disease. - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2009-04-21T09:57:00+00:00","dateModified":"2022-11-10T14:24:14+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-open-label-prospective-randomized-multicenter-study-of-intensive-versus-weekly-granulocyte-and-monocyte-apheresis-in-active-crohns-disease\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/3978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=3978"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=3978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}